Responses
Other content recommended for you
- FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps
- How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
- Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: protocol for the ExPlas study
- Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances
- Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study
- The China Alzheimer Report 2022
- 28 A perfect storm: expanded disease definitions in alzheimer’s disease and the new era of disease-modifying drugs in mild cognitive impairment
- Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
- Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
- FDA calls for investigation into industry influence during Alzheimer’s drug approval